Department of Head and Neck Oncology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, India.
Department of Head and Neck Oncology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, India.
Eur J Surg Oncol. 2019 Nov;45(11):2126-2130. doi: 10.1016/j.ejso.2019.05.018. Epub 2019 May 18.
To study the determinants of locoregional control (LRC) on stage I/II oral squamous cell carcinoma (OSCC) classified by AJCC 8th edition.
Retrospective analysis from 296 patients of pT1-2N0 oral OSCC treated with surgery (wide local excision and selective neck dissection). Those receiving adjuvant therapy were excluded. Multivariate analysis was performed for impact of adverse pathological features (APFs) on LRC.
In stage I, LRC was impacted by perineural invasion (PNI) (HR 7.72, p = 0.010, 95% CI 1.64-36.26) and moderate/poor differentiation (MD/PD) (HR 3.04, p = 0.049, 95% CI 0.99-9.25). In stage II, LRC was impacted by depth of invasion (DOI) (HR 1.59, p = 0.014, 95% CI 1.099-2.32), PNI (HR = 2.86, p = 0.005, 95% CI 1.36-5.98). Combined MD/PD and PNI were associated with worse LRC than either feature individually (HR = 4.12, p < 0.001, 95% CI 2.16-7.85).
PNI and differentiation accurately predict LRC in AJCC 8th edition classified stage I/II OSCC. PNI was a stronger predictor of locoregional failure than DOI in stage II disease. By incorporating these parameters, we can improve precision in staging of early OSCC and identify potential candidates for treatment escalation to improve outcomes.
研究第 8 版 AJCC 分期的 I/II 期口腔鳞状细胞癌(OSCC)局部区域控制(LRC)的决定因素。
回顾性分析了 296 例接受手术(广泛局部切除术和选择性颈部淋巴结清扫术)治疗的 pT1-2N0 口腔 OSCC 患者。排除接受辅助治疗的患者。对不良病理特征(APFs)对 LRC 的影响进行多因素分析。
在 I 期,神经周围侵犯(PNI)(HR 7.72,p=0.010,95%CI 1.64-36.26)和中/低分化(MD/PD)(HR 3.04,p=0.049,95%CI 0.99-9.25)影响 LRC。在 II 期,浸润深度(DOI)(HR 1.59,p=0.014,95%CI 1.099-2.32)和 PNI(HR=2.86,p=0.005,95%CI 1.36-5.98)影响 LRC。MD/PD 与 PNI 联合与任一特征单独相比,LRC 更差(HR=4.12,p<0.001,95%CI 2.16-7.85)。
PNI 和分化准确预测第 8 版 AJCC 分期的 I/II 期 OSCC 的 LRC。在 II 期疾病中,PNI 是局部区域失败的更强预测因子,而不是 DOI。通过纳入这些参数,我们可以提高早期 OSCC 分期的准确性,并确定潜在的治疗升级候选者,以改善预后。